How many investments has Prospect Venture Partners made?

Prospect Venture Partners has 27 tracked investments, 7 of which have exited via acquisition or IPO.

What stage does Prospect Venture Partners invest at?

Prospect Venture Partners invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is Prospect Venture Partners's typical check size?

Prospect Venture Partners typically writes checks of $3M – $5M.

What sectors does Prospect Venture Partners focus on?

Prospect Venture Partners focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.

Where is Prospect Venture Partners located?

Prospect Venture Partners is headquartered in Menlo Park, US.

Does Prospect Venture Partners lead rounds?

Yes, Prospect Venture Partners leads investment rounds.

Who does Prospect Venture Partners co-invest with?

Prospect Venture Partners most often shares deals with New Enterprise Associates (NEA), Aisling Capital, Foresite Capital, among 31 tracked co-investors.

Prospect Venture Partners

Venture capital

Menlo Park · Seed–Late Stage · 3 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Prospect Venture Partners focuses on biomedical innovation, supporting entrepreneurs pursuing growth opportunities across health care, biotechnology, and medical devices. The firm partners closely with management teams to help build strong companies, drawing on a track record established since its founding in 1997.

Invests inBiotech Deep Tech Digital Health Healthtech Medical Devices Menlo Park Palo Alto United States

Source: firm website, verified Aug 3, 2026.

Stage

Seed–Late Stage

Check

$3M – $5M

Menlo Park, California, US

Leads rounds

Leads

Instruments

Equity

Founded

1997

AUM

$100M

Tracked investments

Team · 3 people

from the firm's website & public directories

Alexander E. Barkas· Co-Founder

Alex Barkas was a co-founder of Prospect Ventures, which he established to focus on developing and commercializing biomedical technologies. He previously served as a Partner at Kleiner Perkins Caufield & Byers, where he worked on biotechnology and medical device investing and co-founded and led several biotechnology companies, and earlier founded the healthcare consulting firm BioBridge Associates. He held a PhD in Biology from New York University and a BA in Biology from Brandeis University, with prior research experience at Memorial Sloan Kettering Cancer Center, the Toronto Hospital for Sick Children, the Whitehead Institute at MIT, and Duke University.

David Schnell· Managing Director· Menlo Park, California

David Schnell is a Managing Director who co-founded Prospect Ventures in 1997, a firm focused on biomedical companies. He was previously a Partner at Kleiner Perkins Caufield & Byers, where he invested in early-stage biotechnology companies, and co-founded and served as CEO of Healtheon Corporation, which later merged with WebMD. Earlier he spent seven years at Sandoz Pharmaceuticals (now Novartis) in executive roles; he holds an MD from Harvard Medical School and an MA and BS from Stanford.

d•••@prospectventures.comreveal

Russell Hirsch· Managing Director

Russell Hirsch is a co-founder and Managing Director of Prospect Venture Partners, focusing on life science investments in biotechnology and medical device companies. He previously served as a General Partner at the Mayfield Fund, where he helped build its biotechnology and medical device practice. Before his venture career, he worked as a research scientist, earning his MD and PhD from UCSF and conducting research on hepatitis B viral replication.

r•••@prospectventures.comreveal

What they invest in

from 11 of 28 portfolio companies

Biotech ×8Healthtech ×8Medical Devices ×4Hardware ×2New Materials ×2Advanced Manufacturing ×1Consumer ×1Deep Tech ×1

HQs:United States×8Switzerland×1United Kingdom×1

Investments · 28 tracked

founders shown can be your intro path

By year:2016 · 1 2015 · 23 dated

Insmedinsmed.com in 𝕏NASDAQ: INSM

Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.

BiotechDigital HealthHealthtechMedical Devices

Will LewisinGeoffrey Allanin

Co-investorsBessemer Venture Partners F-Prime Capital Foresite Capital OrbiMed NVIDIA

Curileumcurileum.com in✓ verified

Curileum develops regenerative medicine therapies targeting intestinal stem cells to prevent colorectal cancer.

BiotechHealthtechMedical DevicesLondon, GB

Dr Jeff Moore(Founder & CEO)Jeff Moore(CEO & Founder)

Co-investorsAtlas Venture Biotechnology Value Fund Canaan Partners Oxford Technology Management

Amicus Therapeuticsamicusrx.com in

Amicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions.

BiotechHealthtechCranbury, US

Daphne Quimi(Executive Officer)John Crowley(Executive Officer, Director)William D. Baird, III(Executive Officer)

BoardCraig A. Wheeler(Director)Ted W. Love(Director)Margaret G. McGlynn(Director)

Co-investorsAvoro Capital Advisors Canaan Partners Frazier Life Sciences New Enterprise Associates (NEA)

Amira Pharmaceuticalsacquired by Bristol Myers Squibb

Acquired by Bristol Myers Squibb

Aveo Pharmaceuticals

PartnerRussell Hirsch· led

Cabochon

Complete Genomics

Gloucester Pharmaceuticalsbms.com in 𝕏Acquired

Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.

BiotechHealthtechMedical DevicesNew York, US

Co-investorsKleiner Perkins New Enterprise Associates (NEA)Nextech Invest Rho Capital Partners Rho Ventures RiverVest Venture Partners +2 more

Hansen MedicalMar 2015

HealthtechMountain View, US

William Sutton(Executive Officer)Christopher P. Lowe(Executive Officer, Director)Cary Vance(Executive Officer, Director)Robert Cathcart(Executive Officer)Brian Sheahan(Executive Officer)Joseph Guido(Executive Officer)

PartnerRussell Hirsch· led

Health Systems Technologies

Seattle-based developer of software for managed care.

Idun PharmaceuticalsJul 2015

BiotechSan Diego, US

Steven J. Mento, Ph.D.(Director)David F. Hale(Executive Officer, Director)

BoardPaul Klingenstein(Director)Louis Lacasse(Director)James Scopa(Director)Shahzad Malik(Director)

Co-investorsVenrock

Infinity Pharmaceuticalsinfi.com

Co-investorsAdvent Life Sciences Aisling Capital New Enterprise Associates (NEA)

Jazz Pharmaceuticaljazzpharma.com in 𝕏

Jazz Pharmaceuticals is a biopharmaceutical company developing treatments for rare diseases and cancers, with a focus on oncology and biomarker-driven therapies such as those targeting HER2-expressing cancers.

BiotechHealthtech

Co-investorsLongitude Capital Rex Health Ventures Solas BioVentures

Kythera Biopharmaceuticalsallergan.comAcquired

Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.

Co-investorsAisling Capital ARCH Venture Partners Schooner Capital ALTITUDE LIFE SCIENCE VENTURES Foley Ventures Invus

Millennium Pharmaceuticalsacquired by Takeda Pharmaceutical

Acquired by Takeda Pharmaceutical

PartnerRussell Hirsch· led

Nanosysnanosys.com inAcquired

Nanosys develops Quantum Dot technology and materials, providing samples, R&D collaboration, and scaled production for partners building display and other advanced-material products.

Advanced ManufacturingDeep TechHardwareNew MaterialsSemiconductorsMilpitas, US

Jason Hartlove(Executive Officer, Director)Jian Chen(Executive Officer)Russell Kempt(Executive Officer)Noland Granberry(Executive Officer)

BoardKeith Crandell(Director)Steven Goldby(Director)

Co-investorsStructural Capital TEL Venture Capital, Inc.Venrock ARCH Venture Partners

Ngm Biopharmaceuticals

BiotechSouth San Francisco, US

Jin-Long Chen(Executive Officer, Director)William J. Rieflin(Executive Officer, Director)David V. Goeddel(Director)

BoardPeter Svennilson(Director)inMark Leschly(Director)David Schnell(Director)

Co-investorsForesite Capital The Column Group

Novacept

Co-investorsNew Enterprise Associates (NEA)

Opus Medical

Portola Pharmaceuticalsacquired by Alexion

Pharmaceutical company acquired by Alexion in 2020.

PartnerRussell Hirsch· led

Co-investorsBluebird Ventures Lightstone Ventures

Rinat Neuroscience

Co-investorsSV Health Investors

Senomyxfirmenich.com in 𝕏Acquired

Firmenich is a co-creation and innovation partner specializing in nutrition, health, and beauty ingredients and solutions.

ConsumerHealthtechNew MaterialsGeneva, CH

Gilbert Ghostinein

Co-investorsBay City Capital Rho Ventures

SentreHeartsentreheart.com in 𝕏Sep 2016

SentreHeart appears to now redirect to AtriCure, Inc., a medical device company.

BiotechHardwareHealthtechMedical DevicesRedwood City, US

Russell Seiber(Executive Officer, Director)Pam Simons(Executive Officer)Greg Fung(Executive Officer)Robert Strasser(Executive Officer)

BoardPhil Young(Director)inVictor Tong(Director)

PartnerRussell Hirsch· led

Co-investorsUS Venture Partners

SurgRx

Co-investorsNew Enterprise Associates (NEA)

Tercica

TherOxtherox.com

Co-investorsAPERTURE Venture Partners

Topica Pharmaceuticalsacquired by Medicis

Acquired by Valeant via Medicis

Trubionacquired by Emergent Biosolutions

Acquired by Emergent BioSolutions

Exits · 6

IPOs and acquisitions across the tracked portfolio

InsmedNASDAQ: INSMAmira Pharmaceuticalsacq. by Bristol Myers SquibbMillennium Pharmaceuticalsacq. by Takeda PharmaceuticalPortola Pharmaceuticalsacq. by AlexionTopica Pharmaceuticalsacq. by MedicisTrubionacq. by Emergent Biosolutions

Portfolio news

latest coverage across their companies

BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth - Daily Political

Amicus Therapeutics · dailypolitical.com · Aug 15, 2026

Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWire

Insmed · geekwire.com · Jul 13, 2026

Frequently asked questions

How many investments has Prospect Venture Partners made?: Prospect Venture Partners has 27 tracked investments, 7 of which have exited via acquisition or IPO.
What stage does Prospect Venture Partners invest at?: Prospect Venture Partners invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is Prospect Venture Partners's typical check size?: Prospect Venture Partners typically writes checks of $3M – $5M.
What sectors does Prospect Venture Partners focus on?: Prospect Venture Partners focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
Where is Prospect Venture Partners located?: Prospect Venture Partners is headquartered in Menlo Park, US.
Does Prospect Venture Partners lead rounds?: Yes, Prospect Venture Partners leads investment rounds.
Who does Prospect Venture Partners co-invest with?: Prospect Venture Partners most often shares deals with New Enterprise Associates (NEA), Aisling Capital, Foresite Capital, among 31 tracked co-investors.

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.